Mestinon (Pyridostigmine Bromide)

Pyridostigmine bromide inhibits the enzyme acetylcholinesterase, which normally breaks down acetylcholine at nerve endings. By blocking this enzyme, the drug raises acetylcholine levels in the synaptic cleft, allowing more neurotransmitter to bind to receptors at the neuromuscular junction and thereby strengthening muscle contraction.

The appropriate dose of Mestinon is individualized by the prescribing clinician based on the patient’s condition, severity, renal function, and response to therapy. Dosage adjustments are made during treatment to achieve optimal clinical benefit while minimizing side effects.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited. The medication should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mestinon (pyridostigmine) is a reversible, peripheral‑acting anticholinesterase, whereas other agents such as neostigmine have a shorter duration of action and may affect the central nervous system. Pyridostigmine’s longer half‑life makes it suitable for chronic management of myasthenia gravis, while others are often used for short‑term diagnostic or peri‑operative purposes.

Mestinon tablets should be stored at room temperature, ideally below 25 °C, in their original packaging to protect them from moisture and light. Keeping the product in a dry, cool environment helps maintain its potency throughout its shelf life.

Mestinon is taken orally, usually in tablet form, with or without food as directed by the prescriber. The dose may be divided throughout the day to maintain steady blood levels and to reduce the likelihood of gastrointestinal side effects.

The most critical adverse events include cholinergic crisis, which can cause severe muscle weakness and respiratory failure, and significant bradycardia that may lead to cardiac complications. Prompt medical attention is required if these symptoms develop.

Mestinon is contraindicated in patients with known hypersensitivity to pyridostigmine or any component of the formulation, and it should be avoided in individuals with mechanical intestinal obstruction or severe asthma without careful medical supervision.